Review of materials and fabrication methods for flexible nano and micro-scale physical and chemical property sensors

The use of flexible sensors has tripled over the last decade due to the increased demand in various fields including health monitoring, food packaging, electronic skins and soft robotics. Flexible sensors have the ability to be bent and stretched during use and can still maintain their electrical and mechanical properties. This gives them an advantage over rigid sensors that lose their sensitivity when subject to bending. Advancements in 3D printing have enabled the development of tailored flexible sensors. Various additive manufacturing methods are being used to develop these sensors including inkjet printing, aerosol jet printing, fused deposition modelling, direct ink writing, selective laser melting and others. Hydrogels have gained much attention in the literature due to their self-healing and shape transforming. Self-healing enables the sensor to recover from damages such as cracks and cuts incurred during use, and this enables the sensor to have a longer operating life and stability. Various polymers are used as substrates on which the sensing material is placed. Polymers including polydimethylsiloxane, Poly(N-isopropylacrylamide) and polyvinyl acetate are extensively used in flexible sensors. The most widely used nanomaterials in flexible sensors are carbon and silver due to their excellent electrical properties. This review gives an overview of various types of flexible sensors (including temperature, pressure and chemical sensors), paying particular attention to the application areas and the corresponding characteristics/properties of interest required for such. Current advances/trends in the field including 3D printing, novel nanomaterials and responsive polymers, and self-healable sensors and wearables will also be discussed in more detail

Magnesium nanoparticle synthesis from powders via pulsed laser ablation in liquid for nanocolloid production

Magnesium nanoparticles of various mean diameters (53–239 nm) were synthesised in this study via pulsed laser ablation in liquid (PLAL) from millimetre sized magnesium powders within isopropyl alcohol. It was observed via a 3 × 3 full factorial design of experiments that the processing parameters can control the nanoparticle distribution to produce three size-distribution types (bimodal, skewed and normal). Ablation times of 2, 5, and 25 min where investigated. An ablation time of 2 min produced a bimodal distribution with the other types seen at higher periods of processing. Mg nanoparticle Ultraviolet–Visible spectroscopy (UV–Vis) absorbance at 204 nm increased linearly with increasing ablation time, indicating an increase in nanoparticle count. The colloidal density (mg/mL) generally increased with increasing nanoparticle mean diameter as noted via increasing UV–Vis absorbance. High laser scan speeds (within the studied range of 3000–3500 mm/s) tend to increase the nanoparticle count/yield. For the first time, the effect of scan speed on colloidal density, UV–Vis absorbance and nanoparticle diameter from metallic powder ablation was investigated and is reported herein. The nanoparticles formed dendritic structures after being drop cast on aluminium foil as observed via field emission scanning electron microscope analysis. Dynamic light scattering was used to measure the size of the nanoparticles. Magnesium nanoparticle inks show promise for use in the fabrication conductive tracks or thermal insulation in electronics

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial

Background: Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based antiplatelet therapy. Methods: We did an international, prospective, randomised, open-label, blinded-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset. Participants were assigned in a 1:1 ratio using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based therapy (comprising either clopidogrel alone or combined aspirin and dipyridamole). Randomisation was stratified by country and index event, and minimised with prognostic baseline factors, medication use, time to randomisation, stroke-related factors, and thrombolysis. The ordinal primary outcome was the combined incidence and severity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assessed by central telephone follow-up with masking to treatment assignment, and analysed by intention to treat. This trial is registered with the ISRCTN registry, number ISRCTN47823388. Findings: 3096 participants (1556 in the intensive antiplatelet therapy group, 1540 in the guideline antiplatelet therapy group) were recruited from 106 hospitals in four countries between April 7, 2009, and March 18, 2016. The trial was stopped early on the recommendation of the data monitoring committee. The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline therapy (93 [6%] participants vs 105 [7%]; adjusted common odds ratio [cOR] 0·90, 95% CI 0·67–1·20, p=0·47). By contrast, intensive antiplatelet therapy was associated with more, and more severe, bleeding (adjusted cOR 2·54, 95% CI 2·05–3·16, p<0·0001). Interpretation: Among patients with recent cerebral ischaemia, intensive antiplatelet therapy did not reduce the incidence and severity of recurrent stroke or TIA, but did significantly increase the risk of major bleeding. Triple antiplatelet therapy should not be used in routine clinical practice

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial

Background: Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based antiplatelet therapy.Methods: We did an international, prospective, randomised, open-label, blinded-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset. Participants were assigned in a 1:1 ratio using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based therapy (comprising either clopidogrel alone or combined aspirin and dipyridamole). Randomisation was stratified by country and index event, and minimised with prognostic baseline factors, medication use, time to randomisation, stroke-related factors, and thrombolysis. The ordinal primary outcome was the combined incidence and severity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assessed by central telephone follow-up with masking to treatment assignment, and analysed by intention to treat. This trial is registered with the ISRCTN registry, number ISRCTN47823388.Findings: 3096 participants (1556 in the intensive antiplatelet therapy group, 1540 in the guideline antiplatelet therapy group) were recruited from 106 hospitals in four countries between April 7, 2009, and March 18, 2016. The trial was stopped early on the recommendation of the data monitoring committee. The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline therapy (93 [6%] participants vs 105 [7%]; adjusted common odds ratio [cOR] 0·90, 95% CI 0·67–1·20, p=0·47). By contrast, intensive antiplatelet therapy was associated with more, and more severe, bleeding (adjusted cOR 2·54, 95% CI 2·05–3·16,

The Dynamics of an HIV/AIDS Model with Screened Disease Carriers

The presence of carriers usually complicates the dynamics and prevention of a disease. They are not recognized as disease cases themselves unless they are screened and they usually spread the infection without them being aware. We argue that this has been one of the major causes of the spread of human immunodeficiency virus (HIV). We propose, in this paper, a model for the heterogeneous transmission of HIV/acquired immunodeficiency syndrome in the presence of disease carriers. The model allows us to assess the role of screening, as an intervention program that can slow the epidemic. A threshold value ψ*, for the screening rate is obtained. It is shown numerically that if 80% or more of the carrier population is screened, the epidemic can be contained. The qualitative analysis is done in terms of the model reproduction number R. The model has two equilibria, the disease free equilibrium and a unique endemic equilibrium. The disease free equilibrium is globally stable of R < 1 and the endemic equilibrium is is locally stable for R > 1. A detailed discussion of the model reproduction number is given and numerical simulations are done to show the role of some of the important model parameters

A Treatise of Biological Models

Please help populate SUNScholar with the full text of SU research output. Also - should you need this item urgently, please snd us the details and we will try to get hold of the full text as quick possible. E-mail to [email protected]. Thank you.NatuurwetenskappeWiskund

Drying-off management in dairy farming

(Zimbabwe Veterinary Journal, 1999, 30(3&4): 98-110

A mathematical model for the cannabis epidemic in a South African province with a non-linear incidence rate

A deterministic mathematical model for the dynamics of cannabis use in a South Africa metropolis of Durban is proposed and analysed. To the analysis the model, the important threshold parameter ℛ0 (the basic reproduction number), is determined. It is proved that the model exhibits multiple cannabis persistent equilibria. For ℛ0 1. The model is fitted into the available data and the values of the parameters involved in the model formulation are estimated. Sensitivity analysis of the model, using the parameters involved in the formulation of ℛ0 , is given. Numerical simulation to support the theoretical analysis of the model is provided.This work originated from projects assigned to participants in the 2 nd joint UNISA-UP Work-shop on Mathematical and Theoretical Epidemiology that was held at the University of Pretoria from 2 to 8 March 2015.The DST/NRF SARChI Chair in Mathematical Models and Methods in Bioengineering and Biosciences from the University of Pretoria and University of South Africa.https://www.tandfonline.com/loi/tsms202022-04-18hj2022Mathematics and Applied MathematicsZoology and Entomolog